Alopexx expands its management team with the appointment of Thomas T. Thomas as CFO


Posted: October 20, 2021 at 6:30 a.m. MDT|Update: 3 hours ago

CAMBRIDGE, Mass., 20 October 2021 / PRNewswire / – Alopexx, Inc., a clinical-stage biotechnology company focused on the development of novel, broad-spectrum immune-mediated therapies for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Thomas T. Thomas joined the Company as Chief Financial Officer. Mr. Thomas has over 30 years of financial management and entrepreneurship experience in biotechnology, packaged products, financial services and not-for-profit organizations.

“Thomas brings a broad and diverse financial background to Alopexx and is perfectly suited to help us move the company forward,” said Alopexx CEO Dr. Daniel Vlock.

Mr Thomas added, “I am very excited to join a company focused on creating new vaccines and treatments targeting unmet medical needs for antimicrobial resistance.

Mr. Thomas is the former Interim CEO of the Stupski Foundation (2009-2010). Prior to joining this foundation, Thomas spent twelve years at Genentech, Inc. in various financial roles, as company treasurer from 2001 to 2006. As treasurer, he led the corporate investment program. over $ 6.5 billion from Genentech, implemented and led a business risk management program identifying and mitigating these business risks, partnered with business development for funding Genentech’s pharmaceutical collaborations and also executed large corporate transactions, including the $ 2 billion Global public debt offering and financing and construction of the expansion of the Genentech South Campus research center, in support of Genentech’s rapid growth. Since 2016, Thomas has served as an independent director on the board of directors of Opiant Pharmaceuticals, a NASDAQ company, as chairman of the audit committee and member of the compensation committee and has served on its nominating and governance committee.

Thomas is a Chartered Financial Analyst (CFA). He obtained his MBA from University of Cincinnati College of Business and he holds a Bachelor of Music from the University of Cincinnati College-Conservatory of Music.

About Alopexx, Inc.

Alopexx is a clinical-stage biotechnology company targeting novel immune therapies for the prevention and treatment of bacterial, fungal and parasitic microbial infections. The target of our therapeutics, poly NOT-acetyl glucosamine (PNAG), has been found in a wide variety of pathogens. Our vaccine candidate, AV0328, has been shown to induce protective antibodies against a wide range of pathogens expressing PNAG in a phase 1 trial. F598, our all-human monoclonal antibody, has been shown to be safe and well tolerated. during phase 1 and pilot trials. After a single infusion, it can provide protection for 2 to 3 months.

Our goal is to develop a broad spectrum non-antibiotic therapeutic platform for the treatment and prevention of microbial infections. These immune therapies will reduce dependence on antibiotics and the development of antimicrobial resistance.

For more information, please visit

View original content to download multimedia:

SOURCE Alopexx Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


About Author

Comments are closed.